Irofulven

Drug Profile

Irofulven

Alternative Names: 6-HMAF; E 7850; HMAF; Hydroxymethylacylfulvene; Irofulven-2; LP 184; MGI 114

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Dainippon Sumitomo Pharma; Eisai Co Ltd
  • Class Antineoplastics; Sesquiterpenes; Small molecules
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Renal cell carcinoma; Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 30 Dec 2016 Irofulven licensed to 2X Oncology
  • 30 Dec 2016 Oncology Venture in-licenses Drug Response Prediction (DRP™) technology from Medical Prognosis Institute with three year world-wide exclusivity
  • 22 Sep 2016 Phase II development is ongoing for Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top